Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:35:47 EST Tue 25 Nov 2025
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q1.1126.78·126.861.0126.83+1.561.23,043.2382,47334,931124.78  127.61  124.70128.70  88.57513:18:02Nov 2415 min RT 2¢

Recent Trades - Last 10 of 34931
Time ETExPriceChangeVolume
13:18:10Q126.8871.61711
13:18:09Q126.8351.5651
13:18:07Q126.90421.63422
13:18:06Q126.8351.565181
13:18:05Q126.881.612
13:18:05Q126.881.613
13:18:05Q126.8351.56550
13:18:04Q126.861.5910
13:18:04Q126.8351.565200
13:18:03Q126.841.5710

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-11-24 08:30U:GILDNews ReleaseGilead Foundation Commits Over $3 Million to Address Food Insecurity
2025-11-20 07:02U:GILDNews ReleaseAspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
2025-11-18 05:00U:GILDNews ReleaseGilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
2025-11-13 08:30U:GILDNews ReleaseGilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
2025-11-07 08:30U:GILDNews ReleaseGilead Provides Update on Phase 3 ASCENT-07 Study
2025-11-07 08:00U:GILDNews ReleaseGilead's Livdelzi(TM) Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
2025-11-04 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conferences
2025-11-03 09:10U:GILDNews ReleaseGilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
2025-10-31 08:00U:GILDNews ReleaseGilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo(TM) (Lenacapavir)
2025-10-30 16:02U:GILDNews ReleaseGilead Sciences Announces Third Quarter 2025 Financial Results
2025-10-23 08:00U:GILDNews ReleaseGilead to Showcase Interim Long-Term Efficacy Data for Livdelzi(TM) (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
2025-10-19 08:30U:GILDNews ReleaseGilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
2025-10-19 02:30U:GILDNews ReleaseTrodelvy(TM) Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
2025-10-15 03:30U:GILDNews ReleaseGilead Presents New HIV Research Data at EACS 2025 - Driving Scientific Innovation in Treatment and Prevention
2025-10-13 08:30U:GILDNews ReleaseGilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
2025-10-09 16:05U:GILDNews ReleaseGilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
2025-09-25 08:00U:GILDNews ReleaseGilead Foundation Grants $6.5 Million in Commitment to STEM Education
2025-09-04 14:15U:GILDNews ReleaseGilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
2025-09-04 08:30U:GILDNews ReleaseGilead Sciences Launches Choose U(TM) Campaign Spotlighting the Inspiring Experiences of People Living with HIV
2025-09-03 11:30U:GILDNews ReleaseGilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy